Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
-
Clinical Benefit
Substantial
The actual benefit of RISPERDAL and RISPERDALORO in the treatment of schizophrenia remains substantial.
Clinical Added Value
moderate
Like all other antipsychotics (including typical an tipsychotics), RISPERDAL and RISPERDALORO provide a moderate improvement in actual benefit (IAB III) in the treatment of schizophrenia.
Listen
